Researchers at Juntendo and Hiroshima Universities have found that soluble ST2 (sST2), naturally maintained at high levels in the body, suppresses food allergies by blocking IL-33 signaling. The study identifies fibroblasts as the key sST2-producing cells and points toward new allergy prevention and treatment strategies.
Bankruptcies and closures among Japanese healthcare institutions hit record highs two years running. How suppressed fee schedules, rising costs, and staff shortages combined, and what the 3.09 percent fiscal 2026 revision changes.
Two decades after Shinya Yamanaka's 2006 paper, Japan approved the world's first iPS-derived regenerative medicine products on March 6, 2026: Amchepry for Parkinson's disease and RiHEART for severe heart failure. The trial data, the seven-year clock, and the 55 million yen price.
Meiji University spinout Pormedtec is preparing Japan's first pig-to-human organ transplant trial, now targeted for 2028 at Hokkaido University Hospital and Shonan Kamakura General Hospital. Only about 4% of Japan's 16,000 registered transplant candidates receive an organ each year. In the US, a gene-edited pig kidney has functioned in a patient for more than seven months.
Researchers at Japan's JAIST found that Ewingella americana, a bacterium from Japanese tree frog intestines, completely eliminated colorectal tumors in mice after a single dose, a 100% complete response rate that outperformed chemotherapy and immunotherapy in the same comparison. Here is what the preclinical study showed, and what it does not yet show.
Kagoshima University's oncolytic virus Surv.m-CRA-1 has entered a Phase 3 physician-led trial for primary malignant bone tumors, aiming at full approval. The therapy acts on cancer stem cells that conventional drugs struggle to reach, offering a possible new option for a cancer that has seen no new drug in over 30 years. Inside the mechanism, the Nippon Zoki licensing deal, the 2027 approval target, and what remains unproven.